Background: Chronic rhinosinusitis (CRS) is a prevalent, heterogeneous inflammatory disease associated with significant morbidity. Systemic corticosteroids (SCS) are commonly prescribed for their anti-inflammatory effects, but cumulative exposure carries risks, including metabolic, cardiovascular, and skeletal complications. Despite widespread use, evidence-based guidance on optimal indications, timing, and duration of SCS in CRS remains inconsistent. Methodology/Principal: An evidence-based review was performed using MEDLINE, EMBASE, and Cochrane databases (2013-2023). Studies were screened and categorized into two primary groups: CRS with (CRSwNP) or without (CRSsNP) nasal polyps. Within CRSwNP, evidence was subcategorized by indication, including (1) polyp size reduction, (2) olfactory dysfunction, (3) comorbid disease, and (4) perioperative use, encompassing pre-and postoperative SCS administration. The CRSsNP category
Thamboo, A., Gigliotti, D., De Corso, E., Lee, S., Bleier, B., Chin, C., Corriveau, M.-n., Hox, V., Hopkins, C., Hwang, P., Janjua, A., Klimek, L., Lee, D., Lee, J., Luong, A., Mortuaire, G., Mullol, J., Patel, Z., Scott, J., et al. (2026). Systemic Corticosteroids in the Management of Sinonasal Disease: An Evidence‐Based Expert Review. International Forum of Allergy & Rhinology, 16(8), 852-879. https://doi.org/10.1002/alr.70211 (Original work published 2026)